Journal Article
. 2015 Dec;4().
doi: 10.1186/s40064-015-1440-6.

Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria

B Jahn 1 U Rochau 1 C Kurzthaler 1 M Hubalek 2 R Miksad 3 G Sroczynski 1 M Paulden 4 M Kluibenschädl 1 M Krahn 5 U Siebert 6 
Affiliations
  • PMID: 26693110
  •     35 References
  •     6 citations

Abstract

A Breast Cancer Outcomes model was developed at the ONCOTYROL research center to evaluate personalized test-treatment strategies in Austria. The goal was to evaluate the cost-effectiveness of a new 21-gene assay (ODX) when used in conjunction with the Adjuvant! Online (AO) decision aid to support personalized decisions about use of adjuvant chemotherapy in early-stage breast cancer patients in Austria. We applied a validated discrete-event-simulation model to a hypothetical cohort of 50 years old women over a lifetime horizon. The test-treatment strategies of interest were defined using three-letter acronyms. The first (second, third) letter indicates whether patients with a low (intermediate, high) risk according to AO were tested using ODX (Y yes, N no). The main outcomes were life-years gained, quality-adjusted life-years (QALYs), costs and cost effectiveness. Robustness of the results was tested in sensitivity analyses. Results were compared to a Canadian analysis conducted by the Toronto Health Economics and Technology Assessment Collaborative (THETA). Five of eight strategies were dominated (i.e., more costly and less effective: NNY, NYN, YNN, YNY, YYN). The base-case analysis shows that YYY (ODX provided to all patients) is the most effective strategy and is cost effective with an incremental cost-effectiveness ratio of 15,700 EUR per QALY gained. These results are sensitive to changes in the probabilities of distant recurrence, age and costs of chemotherapy. The results of the base-case analysis were comparable to the THETA results. Based on our analyses, using ODX in addition to AO is effective and cost effective in all women in Austria. The development of future genetic tests may require alternative or additional test-treatment strategies to be evaluated.

Keywords: 21-Gene assay; Adjuvant! Online; Cost effectiveness; Decision-analytic model; Discrete event simulation; Genetic testing.

Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.
Andrew H Briggs, Milton C Weinstein, +4 authors, ISPOR-SMDM Modeling Good Research Practices Task Force.
Value Health, 2012 Sep 25; 15(6). PMID: 22999133
Highly Cited.
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
Peter S Hall, Christopher McCabe, Robert C Stein, David Cameron.
J Natl Cancer Inst, 2011 Dec 06; 104(1). PMID: 22138097
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
H A Azim, S Michiels, +9 authors, C Swanton.
Ann Oncol, 2013 Jan 23; 24(3). PMID: 23337633    Free PMC article.
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
John Hornberger, Leon E Cosler, Gary H Lyman.
Am J Manag Care, 2005 May 19; 11(5). PMID: 15898220
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.
Daphne T Tsoi, Miho Inoue, +2 authors, Kathleen I Pritchard.
Oncologist, 2010 Apr 28; 15(5). PMID: 20421264    Free PMC article.
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Juhi Asad, Allyson F Jacobson, +7 authors, Paul I Tartter.
Am J Surg, 2008 Sep 24; 196(4). PMID: 18809056
Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.
P Sinn, S Aulmann, +6 authors, A Schneeweiss.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(9). PMID: 24771945    Free PMC article.
St. Gallen 2011: Summary of the Consensus Discussion.
Michael Gnant, Nadia Harbeck, Christoph Thomssen.
Breast Care (Basel), 2011 Jun 03; 6(2). PMID: 21633630    Free PMC article.
Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4.
Jonathan Karnon, James Stahl, +3 authors, Jörgen Möller.
Med Decis Making, 2012 Sep 20; 32(5). PMID: 22990085
[Guidelines for health-economic evaluations in Austria].
Evelyn Walter, Susanne Zehetmayr.
Wien Med Wochenschr, 2007 Jan 11; 156(23-24). PMID: 17211768
The influence of a gene expression profile on breast cancer decisions.
Leonard R Henry, Alexander Stojadinovic, +3 authors, Peter W Soballe.
J Surg Oncol, 2009 Feb 11; 99(6). PMID: 19204954
Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Mo Yang, Suja Rajan, Amalia M Issa.
Cancer, 2012 Feb 24; 118(20). PMID: 22359236
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Shelby D Reed, Yanhong Li, Kevin J Anstrom, Kevin A Schulman.
J Clin Oncol, 2009 Apr 01; 27(13). PMID: 19332722
Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Mike Paulden, Jacob Franek, +3 authors, Murray Krahn.
Value Health, 2013 Aug 21; 16(5). PMID: 23947965
Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan.
Masahide Kondo, Shu Ling Hoshi, +2 authors, Masakazu Toi.
Breast Cancer Res Treat, 2007 Dec 14; 112(1). PMID: 18075786
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
S Ward, A Scope, +4 authors, L Wyld.
Health Technol Assess, 2013 Oct 04; 17(44). PMID: 24088296    Free PMC article.
Systematic Review.
Health related quality of life in different states of breast cancer.
Mathias Lidgren, Nils Wilking, Bengt Jönsson, Clas Rehnberg.
Qual Life Res, 2007 May 01; 16(6). PMID: 17468943
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
Genet Med, 2009 Jan 07; 11(1). PMID: 19125125    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.
Andrew H Briggs, Milton C Weinstein, +4 authors, ISPOR-SMDM Modeling Good Research Practices Task Force.
Med Decis Making, 2012 Sep 20; 32(5). PMID: 22990087
Highly Cited.
Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.
Beate Jahn, Ursula Rochau, +7 authors, Uwe Siebert.
Med Decis Making, 2015 Oct 20; 36(3). PMID: 26476865
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.
J Jaime Caro, Andrew H Briggs, +2 authors, ISPOR-SMDM Modeling Good Research Practices Task Force.
Med Decis Making, 2012 Sep 20; 32(5). PMID: 22990082
Highly Cited. Review.
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Josh J Carlson, Joshua A Roth.
Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828    Free PMC article.
Highly Cited. Systematic Review.
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Gary H Lyman, Leon E Cosler, Nicole M Kuderer, John Hornberger.
Cancer, 2007 Feb 22; 109(6). PMID: 17311307
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.
Ruth Oratz, Dev Paul, Allen L Cohn, Scot M Sedlacek.
J Oncol Pract, 2007 Jul 01; 3(4). PMID: 20859407    Free PMC article.
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.
Ruth Oratz, Benjamin Kim, +4 authors, Michael Broder.
J Oncol Pract, 2011 Jul 07; 7(2). PMID: 21731516    Free PMC article.
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.
A Prat, J S Parker, +9 authors, C M Perou.
Ann Oncol, 2012 Apr 26; 23(11). PMID: 22532584    Free PMC article.
Systematic overview of cost-effectiveness thresholds in ten countries across four continents.
Ruth Schwarzer, Ursula Rochau, +13 authors, Uwe Siebert.
J Comp Eff Res, 2015 Oct 23; 4(5). PMID: 26490020
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Shmuel H Klang, Ariel Hammerman, +3 authors, John Hornberger.
Value Health, 2010 Apr 24; 13(4). PMID: 20412544
Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment.
S B Cantor.
Med Decis Making, 1994 Jul 01; 14(3). PMID: 7934713
Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
Masahide Kondo, Shu-Ling Hoshi, +2 authors, Masakazu Toi.
Breast Cancer Res Treat, 2010 Nov 18; 127(3). PMID: 21082239
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E Senkus, S Kyriakides, +5 authors, ESMO Guidelines Working Group.
Ann Oncol, 2013 Aug 24; 24 Suppl 6. PMID: 23970019
Highly Cited.
Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.
Beate Jahn, Ursula Rochau, +9 authors, Uwe Siebert.
BMC Cancer, 2017 Oct 19; 17(1). PMID: 29037213    Free PMC article.
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Shi-Yi Wang, Weixiong Dang, +3 authors, Cary P Gross.
J Clin Oncol, 2018 Apr 17; 36(16). PMID: 29659329    Free PMC article.
Systematic Review.
Cost-effectiveness of precision medicine: a scoping review.
Miriam Kasztura, Aude Richard, +2 authors, Antoine Flahault.
Int J Public Health, 2019 Oct 28; 64(9). PMID: 31650223    Free PMC article.
Systematic Review.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.
Deborah A Marshall, Luiza R Grazziotin, +4 authors, Maarten Ijzerman.
Value Health, 2020 May 12; 23(5). PMID: 32389221    Free PMC article.
BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score.
Mark D Zarella, Rebecca C Heintzelman, Nikolay K Popnikolov, Fernando U Garcia.
BMC Clin Pathol, 2018 Dec 24; 18. PMID: 30574014    Free PMC article.